AWARE ceftaroline surveillance program (2008-2010): Trends in resistance patterns among streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States

Clinical Infectious Diseases

Volumn 55, Issue SUPPL. 3, 2012, Pages

  Pfaller, Michael A ^a   Farrell, David J ^a   Sader, Helio S ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFTAROLINE; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BACTERIUM CULTURE; BACTERIUM ISOLATE; COMMUNITY ACQUIRED PNEUMONIA; DRUG SURVEILLANCE PROGRAM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; HAEMOPHILUS INFLUENZAE; HUMANS; MICROBIAL SENSITIVITY TESTS; MORAXELLA (BRANHAMELLA) CATARRHALIS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

EID: 84865210377     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis561     Document Type: Article

References (37)

1. Critchley IA, Eckburg PB, Jandourek A, Biek D, Friedland HD, Thye DA. Review of ceftaroline fosamil microbiology: integrated FOCUS studies. J Antimicrob Chemother 2011; 66:iii45-51.
2. File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med 2010; 122:130-41.
3. Echols RM, Tillotson GS, Song JX, Tosiello RL. Clinical trial design for mild-to-moderate community-acquired pneumonia-an industry perspective. Clin Infect Dis 2008; 47(Suppl 3):S166-75.
4. Jones RN, Sader HS, Moet GJ, Farrell DJ. Declining antimicrobial susceptibility of Streptococcus pneumoniae in the United States: report from the SENTRY Antimicrobial Surveillance Program (1998-2009). Diagn Microbiol Infect Dis 2010; 68:334-6.
5. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31:347-82.
6. Jones RN, Farrell DJ, Mendes RE, Sader HS. Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study. J Antimi-crob Chemother 2011; 66(Suppl 3):iii69-80.
7. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005; 128:3854-62.
8. Biek D, Critchley IA, Riccobene TA, Thye DA. Ceftaroline fosamil: A novel broad-spectrum cephalosporin with expanded anti-Grampositive activity. J Antimicrob Chemother 2010; 65:iv9-16.
9. Kaushik D, Rathi S, Jain A. Ceftaroline: A comprehensive update. Int J Antimicrob Agents 2011; 37:389-95.
10. Laudano JB. Ceftaroline fosamil: A new broad-spectrum cephalospo-rin. J Antimicrob Chemother 2011; 66:iii11-18.
11. Mushtaq S, Warner M, Ge Y, Kaniga K, Livermore DM. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother 2007; 60:300-11.
12. File TM Jr., Low DE, Eckburg PB, et al. FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011; 66(Suppl 3):iii19-32.
13. Low DE, File TM Jr, Eckburg PB, et al. FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011; 66(Suppl 3):iii33-44.
14. Corey GR, Wilcox MH, Talbot GH. CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65(Suppl 4):iv41-51.
15. Wilcox MH, Corey GR, Talbot GH. CANVAS 2: the second phase III, randomized double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65:iv53-65.
16. Teflaro (ceftaroline fosamil). Package insert. St. Louis, MO: Forest Pharmaceuticals, Inc.; 2010.
17. Tygacil (tigecycline). Package insert. Philadelphia, PA: Wyeth Pharmaceuticals, Inc.; 2005.
18. Clinical and Laboratory Standards Institute. M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobi-cally; approved standard. 8th ed. Wayne, PA: Clinical and Laboratory Standards Institute, 2012.
19. Clinical and Laboratory Standards Institute. M100-S22. Performance standards for antimicrobial susceptibility testing: 22nd informational supplement. Wayne, PA: Clinical and Laboratory Standards Institute, 2012.
20. Clinical and Laboratory Standards Institute. M45-A. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria. Wayne, PA: Clinical and Laboratory Standards Institute, 2006.
21. Brown SD, Traczewski MM. In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing. Antimicrob Agents Chemother 2009; 53:1271-4.
22. Kollef MH. New antimicrobial agents for methicillin-resistant Staph-ylococcus aureus. Crit Care Resusc 2009; 11:282-6.
23. Fenoll A, Aguilar L, Robledo O, et al. In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime. Antimicrob Agents Chemother 2008; 52:4209-10.
24. Iizawa Y, Nagai J, Ishikawa T, et al. In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599. J Infect Chemother 2004; 10:146-56.
25. Jones RN, Fritsche TR, Ge Y, Kaniga K, Sader HS. Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests. J Antimicrob Chemother 2005; 56:1047-52.
26. McGee L, Biek D, Ge Y, et al. In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2009; 53:552-6.
27. Morrissey I, Ge Y, Janes R. Activity of the new cephalosporin ceftaro-line against bacteraemia isolates from patients with community-acquired pneumonia. Int J Antimicrob Agents 2009; 33:515-9.
28. Patel SN, Pillai DR, Pong-Porter S, McGeer A, Green K, Low DE. In vitro activity of ceftaroline, ceftobiprole and cethromycin against clinical isolates of Streptococcus pneumoniae collected from across Canada between 2003 and 2008. J Antimicrob Chemother 2009; 64:659-60.
29. Jones RN, Jacobs MR, Sader HS. Evolving trends in Streptococcus pneu-moniae resistance: implications for therapy of community-acquired bacterial pneumonia. Int J Antimicrob Agents 2010; 36:197-204.
30. Jacobs MR, Good CE, Windau AR, et al. Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 2010; 54:2716-9.
31. Sader HS, Fritsche TR, Kaniga K, Ge Y, Jones RN. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother 2005; 49:3501-12.
32. Panagiotidis G, Backstrom T, Asker-Hagelberg C, Jandourek A, Weintraub A, Nord CE. Effect of ceftaroline on normal human intestinal microflora. Antimicrob Agents Chemother 2010; 54:1811-4.
33. Vidaillac C, Leonard SN, Sader HS, Jones RN, Rybak MJ. In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant Gram-negative pathogens, including beta-lactamase-pro-ducing enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009; 53:2360-6.
34. Pankuch GA, Appelbaum PC. Postantibiotic effect of ceftaroline against Gram-positive organisms. Antimicrob Agents Chemother 2009; 53:4537-9.
35. Ramirez JA, Anzueto AR. Changing needs of community-acquired pneumonia. J Antimicrob Chemother 2011; 66 (Suppl 3):iii3-ii9.
36. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44(Suppl 2):S27-72.
37. Spellberg B, Fleming TR, Gilbert DN. Executive summary: workshop on issues in the design and conduct of clinical trials of antibacterial drugs in the treatment of community-acquired pneumonia. Clin Infect Dis. 2008; 47(Suppl 3):S105-7.